Literature DB >> 34158918

Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry.

Hilary M DuBrock1, Charles D Burger2, Sonja D Bartolome3, Jeremy P Feldman4, D Dunbar Ivy5, Erika B Rosenzweig6, Jeffrey S Sager7, Kenneth W Presberg8, Stephen C Mathai9, Matthew R Lammi10, James R Klinger11, Michael Eggert12, Teresa De Marco13, Jean M Elwing14, David Badesch15, Todd M Bull15, Linda M Cadaret16, Gautam Ramani17, Thenappan Thenappan18, H James Ford19, Nadine Al-Naamani20, Marc A Simon21,22, Sula Mazimba23, James R Runo24, Murali Chakinala25, Evelyn M Horn26, John J Ryan27, Robert P Frantz28, Michael J Krowka1.   

Abstract

Compared to idiopathic pulmonary arterial hypertension (IPAH), patients with portopulmonary hypertension (POPH) have worse survival. Health disparities may contribute to these differences but have not been studied. We sought to compare socioeconomic factors in patients with POPH and IPAH and to determine whether socioeconomic status and/or POPH diagnosis were associated with treatment and health-care utilization. We performed a cross-sectional study of adults enrolled in the Pulmonary Hypertension Association Registry. Patients with IPAH (n = 344) and POPH (n = 57) were compared. Compared with IPAH, patients with POPH were less likely to be college graduates (19.6% vs. 34.9%, p = 0.02) and more likely to be unemployed (54.7% vs. 30.5%, p < 0.001) and have an annual household income below poverty level (45.7% vs. 19.0%, p < 0.001). Patients with POPH had similar functional class, quality of life, 6-min walk distance, and mean pulmonary arterial pressure with a higher cardiac index. Compared with IPAH, patients with POPH were less likely to receive combination therapy (46.4% vs. 62.2%, p = 0.03) and endothelin receptor antagonists (28.6% vs. 55.1%, p < 0.001) at enrollment with similar treatment at follow-up. Patients with POPH had more emergency department visits (1.7 ± 2.1 vs. 0.9 ± 1.2, p = 0.009) and hospitalizations in the six months preceding enrollment (1.5 ± 2.1 vs. 0.8 ± 1.1, p = 0.02). Both POPH diagnosis and lower education level were independently associated with a higher number of emergency department visits. Compared to IPAH, patients with POPH have lower socioeconomic status, are less likely to receive initial combination therapy and endothelin receptor antagonists but have similar treatment at follow-up, and have increased health-care utilization.
© The Author(s) 2021.

Entities:  

Keywords:  health-care utilization; pulmonary hypertension; socioeconomic status

Year:  2021        PMID: 34158918      PMCID: PMC8186121          DOI: 10.1177/20458940211020913

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  26 in total

1.  Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.

Authors:  Athénaïs Boucly; Jason Weatherald; Laurent Savale; Xavier Jaïs; Vincent Cottin; Grégoire Prevot; François Picard; Pascal de Groote; Mitja Jevnikar; Emmanuel Bergot; Ari Chaouat; Céline Chabanne; Arnaud Bourdin; Florence Parent; David Montani; Gérald Simonneau; Marc Humbert; Olivier Sitbon
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 2.  Pulmonary-Hepatic vascular Disorders (PHD).

Authors:  R Rodríguez-Roisin; M J Krowka; Ph Hervé; M B Fallon
Journal:  Eur Respir J       Date:  2004-11       Impact factor: 16.671

3.  International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension.

Authors:  Michael J Krowka; Michael B Fallon; Steven M Kawut; Valentin Fuhrmann; Julie K Heimbach; Michael A E Ramsay; Olivier Sitbon; Ronald J Sokol
Journal:  Transplantation       Date:  2016-07       Impact factor: 4.939

4.  Outcomes of Pulmonary Arterial Hypertension Are Improved in a Specialty Care Center.

Authors:  Hongyang Pi; Chad M Kosanovich; Adam Handen; Michael Tao; Jacqueline Visina; Gabrielle Vanspeybroeck; Marc A Simon; Michael G Risbano; Aken Desai; Michael A Mathier; Belinda N Rivera-Lebron; Quyen Nguyen; Jennifer Kliner; Mehdi Nouraie; Stephen Y Chan
Journal:  Chest       Date:  2020-02-25       Impact factor: 9.410

5.  Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation.

Authors:  M J Krowka; D J Plevak; J Y Findlay; C B Rosen; R H Wiesner; R A Krom
Journal:  Liver Transpl       Date:  2000-07       Impact factor: 5.799

6.  Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

Authors:  David B Badesch; Gary E Raskob; C Greg Elliott; Abby M Krichman; Harrison W Farber; Adaani E Frost; Robyn J Barst; Raymond L Benza; Theodore G Liou; Michelle Turner; Scott Giles; Kathy Feldkircher; Dave P Miller; Michael D McGoon
Journal:  Chest       Date:  2009-10-16       Impact factor: 9.410

7.  Socioeconomic status affects pulmonary hypertension disease severity at time of first evaluation.

Authors:  Arunabh Talwar; Sonu Sahni; Ankoor Talwar; Nina Kohn; James R Klinger
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

Review 8.  Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.

Authors:  Anhua Wei; Zhichun Gu; Juan Li; Xiaoyan Liu; Xiaofan Wu; Yi Han; Jun Pu
Journal:  J Am Heart Assoc       Date:  2016-10-26       Impact factor: 5.501

9.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; David Montani; David S Celermajer; Christopher P Denton; Michael A Gatzoulis; Michael Krowka; Paul G Williams; Rogerio Souza
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

10.  Macitentan Improves Risk Categorization for Liver Transplant Mortality in Patients With Portopulmonary Hypertension: A PORTICO Study Post Hoc Analysis.

Authors:  Michael Krowka; Emmanuelle Cottreel; Marius M Hoeper; Nick H Kim; Nicolas Martin; Olivier Sitbon; Jaume Bosch
Journal:  Liver Transpl       Date:  2020-04-30       Impact factor: 5.799

View more
  4 in total

1.  On errata and corrigenda-The Pulmonary Hypertension Association Registry (PHAR).

Authors:  Kayleen Williams; Noah A Kime; Richard A Kronmal; Nadine Al-Naamani
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

2.  Social determinants of health in pulmonary arterial hypertension patients in the United States: Clinician perspective and health policy implications.

Authors:  Vijay R Nadipelli; Jean M Elwing; Willie H Oglesby; Karim El-Kersh
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

3.  The Different Effects of Direct Bilirubin on Portopulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension.

Authors:  Yuan Li; Hongling Qiu; Qinhua Zhao; Jing He; Rong Jiang; Wenhui Wu; Cijun Luo; Huiting Li; Lan Wang; Jinming Liu; Sugang Gong
Journal:  Int J Clin Pract       Date:  2022-02-03       Impact factor: 3.149

Review 4.  Gender dimension in cardio-pulmonary continuum.

Authors:  Leah Hernandez; Agne Laucyte-Cibulskiene; Liam J Ward; Alexandra Kautzky-Willer; Maria-Trinidad Herrero; Colleen M Norris; Valeria Raparelli; Louise Pilote; Peter Stenvinkel; Karolina Kublickiene
Journal:  Front Cardiovasc Med       Date:  2022-08-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.